51 related articles for article (PubMed ID: 38512249)
21. Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease.
Dana J; Venkatasamy A; Saviano A; Lupberger J; Hoshida Y; Vilgrain V; Nahon P; Reinhold C; Gallix B; Baumert TF
Hepatol Int; 2022 Jun; 16(3):509-522. PubMed ID: 35138551
[TBL] [Abstract][Full Text] [Related]
22. Apelin and the gut microbiome: Potential interaction in human MASLD.
Effenberger M; Grander C; Hausmann B; Enrich B; Pjevac P; Zoller H; Tilg H
Dig Liver Dis; 2024 Jun; 56(6):932-940. PubMed ID: 38087672
[TBL] [Abstract][Full Text] [Related]
23. The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes.
Bridi L; Agrawal S; Tesfai K; Madamba E; Bettencourt R; Richards LM; Khera AV; Loomba R; Ajmera V
Aliment Pharmacol Ther; 2024 Jun; ():. PubMed ID: 38825972
[TBL] [Abstract][Full Text] [Related]
24. Impact of Longitudinal Alcohol Use Patterns on Long-Term Risk of Cirrhosis Among US Veterans With Steatotic Liver Disease.
Wong RJ; Yang Z; Cheung R; Singal AK; Do A; Ahmed A; Yeoh A
Gastroenterology; 2024 Jun; 166(6):1156-1165.e4. PubMed ID: 38428619
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal Follow-Up of Fibrosis-4 in Patients at Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease Receiving Low-Dose Methotrexate Treatment.
Cui J; Di Martino V; Solomon DH
Clin Gastroenterol Hepatol; 2024 Apr; ():. PubMed ID: 38663834
[TBL] [Abstract][Full Text] [Related]
26. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
Boursier J; Hagström H; Ekstedt M; Moreau C; Bonacci M; Cure S; Ampuero J; Nasr P; Tallab L; Canivet CM; Kechagias S; Sánchez Y; Dincuff E; Lucena A; Roux M; Riou J; Trylesinski A; Romero-Gomez M
J Hepatol; 2022 May; 76(5):1013-1020. PubMed ID: 35063601
[TBL] [Abstract][Full Text] [Related]
27. AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD.
Pennisi G; Enea M; Pandolfo A; Celsa C; Antonucci M; Ciccioli C; Infantino G; La Mantia C; Parisi S; Tulone A; Di Marco V; Craxì A; Cammà C; Petta S
Clin Gastroenterol Hepatol; 2023 May; 21(5):1293-1302.e5. PubMed ID: 35842119
[TBL] [Abstract][Full Text] [Related]
28. Prediction of Liver-Related Events With a Combination of Liver Stiffness Measurements and Controlled Attenuation Parameters in Japanese Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease.
Hayashi H; Kamada Y; Fujii H; Takahashi H; Oeda S; Iwaki M; Kawaguchi T; Tomita E; Yoneda M; Tokushige A; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T;
Ultrasound Med Biol; 2023 Jul; 49(7):1658-1664. PubMed ID: 37120329
[TBL] [Abstract][Full Text] [Related]
29. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.
Sanyal AJ; Foucquier J; Younossi ZM; Harrison SA; Newsome PN; Chan WK; Yilmaz Y; De Ledinghen V; Costentin C; Zheng MH; Wai-Sun Wong V; Elkhashab M; Huss RS; Myers RP; Roux M; Labourdette A; Destro M; Fournier-Poizat C; Miette V; Sandrin L; Boursier J
J Hepatol; 2023 Feb; 78(2):247-259. PubMed ID: 36375686
[TBL] [Abstract][Full Text] [Related]
30. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.
Siddiqui MS; Vuppalanchi R; Van Natta ML; Hallinan E; Kowdley KV; Abdelmalek M; Neuschwander-Tetri BA; Loomba R; Dasarathy S; Brandman D; Doo E; Tonascia JA; Kleiner DE; Chalasani N; Sanyal AJ;
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):156-163.e2. PubMed ID: 29705261
[TBL] [Abstract][Full Text] [Related]
31. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease.
Lin H; Lee HW; Yip TC; Tsochatzis E; Petta S; Bugianesi E; Yoneda M; Zheng MH; Hagström H; Boursier J; Calleja JL; Goh GB; Chan WK; Gallego-Durán R; Sanyal AJ; de Lédinghen V; Newsome PN; Fan JG; Castéra L; Lai M; Harrison SA; Fournier-Poizat C; Wong GL; Pennisi G; Armandi A; Nakajima A; Liu WY; Shang Y; de Saint-Loup M; Llop E; Teh KK; Lara-Romero C; Asgharpour A; Mahgoub S; Chan MS; Canivet CM; Romero-Gomez M; Kim SU; Wong VW;
JAMA; 2024 Apr; 331(15):1287-1297. PubMed ID: 38512249
[TBL] [Abstract][Full Text] [Related]
32. American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases.
Singh S; Muir AJ; Dieterich DT; Falck-Ytter YT
Gastroenterology; 2017 May; 152(6):1544-1577. PubMed ID: 28442120
[TBL] [Abstract][Full Text] [Related]
33. Granulocyte colony-stimulating factor with or without stem or progenitor cell or growth factors infusion for people with compensated or decompensated advanced chronic liver disease.
Colli A; Fraquelli M; Prati D; Casazza G
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD013532. PubMed ID: 37278488
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
